Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Amortization of Deferred Charges (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Amortization of Deferred Charges for 16 consecutive years, with $357000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Amortization of Deferred Charges rose 301.12% to $357000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $796000.0, a 166.22% increase, with the full-year FY2024 number at $327000.0, up 16.79% from a year prior.
  • Amortization of Deferred Charges was $357000.0 for Q3 2025 at Harvard Bioscience, up from $210000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $357000.0 in Q3 2025 to a low of $70000.0 in Q1 2021.
  • A 5-year average of $98157.9 and a median of $70000.0 in 2021 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: fell 29.29% in 2021, then skyrocketed 301.12% in 2025.
  • Harvard Bioscience's Amortization of Deferred Charges stood at $70000.0 in 2021, then changed by 0.0% to $70000.0 in 2022, then changed by 0.0% to $70000.0 in 2023, then skyrocketed by 40.0% to $98000.0 in 2024, then soared by 264.29% to $357000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Amortization of Deferred Charges are $357000.0 (Q3 2025), $210000.0 (Q2 2025), and $131000.0 (Q1 2025).